APA (7th ed.) Citation

A, d. B., RJ, S., AC, V., MJJ, P., JG, B., L, d. M., . . . GAP, N. (2024). Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study. Cancers, 16(24), . https://doi.org/10.3390/cancers16244188

Chicago Style (17th ed.) Citation

A, de Bruijn, et al. "Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study." Cancers 16, no. 24 (2024). https://doi.org/10.3390/cancers16244188.

MLA (9th ed.) Citation

A, de Bruijn, et al. "Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study." Cancers, vol. 16, no. 24, 2024, https://doi.org/10.3390/cancers16244188.